Cox univariate and multivariate analysis for overall survival in relapsed or refractory AML patients treated with tipifarnib
| Characteristic . | No. patients . | % . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |||
| Age* | 1.2 | 0.68-2.14 | .53 | — | — | — | ||
| Older than 63 y | 25 | 53 | ||||||
| 63 y or younger | 27 | 47 | ||||||
| Sex | 0.768 | 0.45-1.33 | .34 | — | — | — | ||
| Male | 28 | 48 | ||||||
| Female | 30 | 52 | ||||||
| AML class | 0.645 | 0.38-1.11 | .11 | — | — | — | ||
| Relapsed | 31 | 53 | ||||||
| Refractory | 27 | 47 | ||||||
| Favorable karyotype | 0.97 | 0.54-1.72 | .93 | — | — | — | ||
| No | 40 | 69 | ||||||
| Yes | 18 | 31 | ||||||
| Baseline WBC | 1.71 | 0.88-3.34 | .11 | — | — | — | ||
| 30 × 109/L or more | 11 | 19 | ||||||
| Less than 30 × 109/L | 47 | 81 | ||||||
| ECOG prognostic score | 2.41 | 1.2-4.84 | .013 | 2.751 | 1.30-5.81 | .008 | ||
| Over 1 | 11 | 19 | ||||||
| 0 to 1 | 47 | 81 | ||||||
| Baseline BM blasts | 2.16 | 1.23-3.85 | .007 | 2.17 | 1.18-4.0 | .013 | ||
| Less than 40% | 23 | 40 | ||||||
| 40% or more | 35 | 60 | ||||||
| Bullinger CCP | 2.11 | 1.19-3.73 | .01 | 1.54 | 0.81-2.93 | .19 | ||
| Less than 208 | 26 | 45 | ||||||
| 208 or more | 32 | 55 | ||||||
| RASGRP1/APTX | 2.94 | 1.69-5.3 | < .001 | 3.34 | 1.79-6.25 | < .001 | ||
| Less than −1.102 | 28 | 48 | ||||||
| −1.102 or more | 30 | 52 | ||||||
| Characteristic . | No. patients . | % . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |||
| Age* | 1.2 | 0.68-2.14 | .53 | — | — | — | ||
| Older than 63 y | 25 | 53 | ||||||
| 63 y or younger | 27 | 47 | ||||||
| Sex | 0.768 | 0.45-1.33 | .34 | — | — | — | ||
| Male | 28 | 48 | ||||||
| Female | 30 | 52 | ||||||
| AML class | 0.645 | 0.38-1.11 | .11 | — | — | — | ||
| Relapsed | 31 | 53 | ||||||
| Refractory | 27 | 47 | ||||||
| Favorable karyotype | 0.97 | 0.54-1.72 | .93 | — | — | — | ||
| No | 40 | 69 | ||||||
| Yes | 18 | 31 | ||||||
| Baseline WBC | 1.71 | 0.88-3.34 | .11 | — | — | — | ||
| 30 × 109/L or more | 11 | 19 | ||||||
| Less than 30 × 109/L | 47 | 81 | ||||||
| ECOG prognostic score | 2.41 | 1.2-4.84 | .013 | 2.751 | 1.30-5.81 | .008 | ||
| Over 1 | 11 | 19 | ||||||
| 0 to 1 | 47 | 81 | ||||||
| Baseline BM blasts | 2.16 | 1.23-3.85 | .007 | 2.17 | 1.18-4.0 | .013 | ||
| Less than 40% | 23 | 40 | ||||||
| 40% or more | 35 | 60 | ||||||
| Bullinger CCP | 2.11 | 1.19-3.73 | .01 | 1.54 | 0.81-2.93 | .19 | ||
| Less than 208 | 26 | 45 | ||||||
| 208 or more | 32 | 55 | ||||||
| RASGRP1/APTX | 2.94 | 1.69-5.3 | < .001 | 3.34 | 1.79-6.25 | < .001 | ||
| Less than −1.102 | 28 | 48 | ||||||
| −1.102 or more | 30 | 52 | ||||||
— indicates not applicable.
63 years was the median age for the whole population.